FDA Accepts Pfizer ’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec

NEW YORK--(BUSINESS WIRE) June 27, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news